TABLE 2.
Baseline characteristics of studies with the control group.
| Reference | Area | (R)-CDOP | (R)-CHOP | Population | Cycles (n) | Interval (days) | Median follow-up (months) | Toxicity grading system | Outcome indicators | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Median age (years) | Female (%) | N | Median age (years) | Female (%) | ||||||||
| Zhou (2015) | China | 41 | 67 | 51 | 62 | 68 | 45 | DLBCL | 6 | 21 | 28 | CTCAE 3.0 | ①③④ |
| Shao et al. (2020) | China | 33 | 63 | 46 | 45 | 61 | 47 | DLBCL | 8 | 21 | 24 | Grades NOS | ①②③④ |
| Zheng et al. (2018) | China | 21 | 62 | 48 | 21 | 62 | 43 | NHL | 6 | 21 | 36 | Grades NOS | ①② |
| Li et al. (2016) | China | 25 | 69 | 44 | 25 | 68 | 40 | DLBCL | 4–6 | 21 | 18 | Grades NOS | ①②③④ |
| Huang and Luo (2016) | China | 25 | 47 | 50 | 25 | 44 | 60 | DLBCL | 6–8 | 21 | 24 | CTCAE 4.0 | ① |
| Huang et al. (2021) | China | 15 | 54 | 47 | 15 | 54 | 40 | NHL | 4 | NR | NR | Grades NOS | ① |
| Ye, J (2022) | China | 44 | 48 | 46 | 44 | 46 | 50 | NHL | NR | NR | 6 | Grades NOS | ① |
| Chang and Zhu (2021) | China | 37 | 57 | 54 | 39 | 51 | 67 | DLBCL | NR | 21 | NR | CTCAE 5.0 | ①② |
| Li and Hu (2018) | China | 34 | NR | NR | 30 | NR | NR | DLBCL | 6 | 21 | NR | WHO | ①②③④ |
| Wu et al. (2020) | China | 23 | 56 | 52 | 23 | 52 | 61 | DLBCL | 2 | 21 | NR | CTCAE 5.0 | ①②③④ |
| Liu et al. (2021) | China | 83 | 69 | 59 | 45 | 70 | 44 | PTCL | 6 | 21 | 12 | Grades NOS | ① |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin’s lymphoma; PTCL, peripheral T-cell lymphoma; NR, not reported; CTCAE, Common Terminology Criteria for Adverse Events; WHO, World Health Organization; NOS, not otherwise specified; and outcome indicators (① total cardiovascular adverse events; ② non-serious cardiovascular adverse events; ③ serious cardiovascular adverse events; and ④ heart failure).